Rapidly progressive glomerulonephritis is stologically characterised by the presence of numerous –
**Core Concept**
Rapidly progressive glomerulonephritis (RPGN) is a syndrome characterized by a rapid decline in renal function, often leading to end-stage renal disease within weeks to months. The underlying pathology involves an immune-mediated injury to the glomeruli, leading to crescent formation and eventual destruction of the renal tissue.
**Why the Correct Answer is Right**
The presence of numerous crescents, specifically epithelial crescents, is a hallmark of RPGN. These crescents are composed of proliferating parietal epithelial cells, macrophages, and fibroblasts that accumulate in response to glomerular injury. The formation of crescents is mediated by the activation of various immune cells and the release of pro-inflammatory cytokines, which ultimately lead to the destruction of the glomerular tuft and the loss of renal function.
**Why Each Wrong Option is Incorrect**
**Option A:** **Proliferation of mesangial cells** is not a characteristic feature of RPGN, as mesangial cell proliferation is more commonly seen in conditions such as IgA nephropathy and membranoproliferative glomerulonephritis.
**Option B:** **Fibrinoid necrosis** is a feature of certain vasculitic conditions, but it is not a hallmark of RPGN. Fibrinoid necrosis involves the deposition of fibrin and other proteins in the walls of blood vessels, leading to their destruction.
**Option C:** **Pigment casts** are more commonly seen in conditions such as acute tubular necrosis, where there is damage to the renal tubules leading to the release of pigmented granules into the urine.
**Clinical Pearl / High-Yield Fact**
RPGN is often associated with the presence of anti-GBM antibodies, which target the glomerular basement membrane and lead to its destruction. This is a classic example of an immune-mediated injury to the kidneys, and prompt recognition and treatment are essential to prevent progression to end-stage renal disease.
**Correct Answer: C. Fibrinoid necrosis**